Chronimed
This article was originally published in The Gray Sheet
Executive Summary
Select GT blood glucose monitor warning letter response filed with FDA March 22 addresses agency concerns "satisfactorily," FDA says in an April 23 follow-up letter. The agency issued the warning letter March 3, citing the device for lack of 510(k) clearance ("The Gray Sheet" March 29, p. 20). However, the agency appears satisfied with the firm's response that the device was covered under a "note-to-file" provision in the firm's February 1997 510(k) for its Supreme II monitor. The agency plans to confirm adequacy of the company's corrective action plan during a routine audit shortly
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.